Literature DB >> 19594634

Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments.

Gabriel A Rabinovich1, Juan M Ilarregui.   

Abstract

The immune system has evolved sophisticated mechanisms composed of several checkpoints and fail-safe processes that enable it to orchestrate innate and adaptive immunity, while at the same time limiting aberrant or unfaithful T-cell function. These multiple regulatory pathways take place during the entire life-span of T cells including T-cell development, homing, activation, and differentiation. Galectin-1, an endogenous glycan-binding protein widely expressed at sites of inflammation and tumor growth, controls a diversity of immune cell processes, acting either extracellularly through specific binding to cell surface glycan structures or intracellularly through modulation of pathways that remain largely unexplored. In this review, we highlight the discoveries that have led to our current understanding of the role of galectin-1 in distinct immune cell process, particularly those associated with T-cell homeostasis. Also, we emphasize findings emerging from the study of experimental models of autoimmunity, chronic inflammation, fetomaternal tolerance, and tumor growth, which have provided fundamental insights into the critical role of galectin-1 and its specific saccharide ligands in immunoregulation. Challenges for the future will embrace the rational manipulation of galectin-1-glycan interactions both towards attenuating immune responses in autoimmune diseases, graft rejection, and recurrent fetal loss, while at the same overcoming immune tolerance in chronic infections and cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19594634     DOI: 10.1111/j.1600-065X.2009.00787.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  39 in total

1.  Galectins regulate the inflammatory response in airway epithelial cells exposed to microbial neuraminidase by modulating the expression of SOCS1 and RIG1.

Authors:  Mihai Nita-Lazar; Aditi Banerjee; Chiguang Feng; Gerardo R Vasta
Journal:  Mol Immunol       Date:  2015-09-06       Impact factor: 4.407

Review 2.  Expanding the universe of cytokines and pattern recognition receptors: galectins and glycans in innate immunity.

Authors:  Juan P Cerliani; Sean R Stowell; Iván D Mascanfroni; Connie M Arthur; Richard D Cummings; Gabriel A Rabinovich
Journal:  J Clin Immunol       Date:  2010-12-24       Impact factor: 8.317

Review 3.  Nuclear transport of galectin-3 and its therapeutic implications.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Semin Cancer Biol       Date:  2014-03-19       Impact factor: 15.707

4.  Structural basis of redox-dependent modulation of galectin-1 dynamics and function.

Authors:  Carlos M Guardia; Julio J Caramelo; Madia Trujillo; Santiago P Méndez-Huergo; Rafael Radi; Darío A Estrin; Gabriel A Rabinovich
Journal:  Glycobiology       Date:  2014-01-21       Impact factor: 4.313

5.  Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.

Authors:  Xinqi Wu; Jingjing Li; Erin M Connolly; Xiaoyun Liao; Jing Ouyang; Anita Giobbie-Hurder; Donald Lawrence; David McDermott; George Murphy; Jun Zhou; Matthias Piesche; Glenn Dranoff; Scott Rodig; Margaret Shipp; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2017-05-04       Impact factor: 11.151

6.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

7.  The clinical implication of tumoral Gal-1 expression in laryngeal squamous cell carcinomas.

Authors:  J Ye; H Liu; Y Hu; G Wan; J Li; Z Wang; P Li; G Zhang; Y Li
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

8.  Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior.

Authors:  Florence Lefranc; Véronique Mathieu; Robert Kiss
Journal:  World J Biol Chem       Date:  2011-09-26

9.  The involvement of CD146 and its novel ligand Galectin-1 in apoptotic regulation of endothelial cells.

Authors:  Nathalie Jouve; Nicolas Despoix; Marion Espeli; Laurent Gauthier; Sophie Cypowyj; Karim Fallague; Claudine Schiff; Françoise Dignat-George; Frédéric Vély; Aurélie S Leroyer
Journal:  J Biol Chem       Date:  2012-12-07       Impact factor: 5.157

Review 10.  Glycobiology of cell death: when glycans and lectins govern cell fate.

Authors:  R G Lichtenstein; G A Rabinovich
Journal:  Cell Death Differ       Date:  2013-05-24       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.